2026-07-24T06:25:19Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/230472024-11-28T17:20:53Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16960col_20.500.12105_16967
Repisalud author Gutierrez, Antonio author Bento, Leyre author Diaz-Lopez, Antonio author Barranco, Gilberto author Garcia Recio, Marta author Lopez-Guillermo, Armando author Dlouhy, Ivan author Rovira, Jordina author Rodriguez, Mario author Sanchez Pina, Jose Maria author Baile, Monica author Martin, Alejandro author Novelli, Silvana author Sancho, Juan-Manuel author Garcia, Olga author Salar, Antonio author Bastos-Oreiro, Mariana author Rodriguez-Salazar, Maria Jose author Fernandez, Ruben author de la Cruz, Fatima author Queizan, Jose Antonio author Gonzalez de Villambrosia, Sonia author Cordoba, Raul author Lopez, Andres author Luzardo, Hugo author Garcia, Daniel author Sastre-Serra, Jorge author Garcia, Juan Fernando author Montalban, Carlos author Cabanillas, Fernando author Rodriguez, Jose 2024-09-13T09:16:03Z 2024-09-13T09:16:03Z 2020-05 Gutierrez A, Bento L, Diaz-Lopez A, Barranco G, Garcia Recio M, Lopez-Guillermo A, et al. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2020 May;104(5):400-8. Epub 2020 Feb 18. 10.1111/ejh.13364 1600-0609 0902-4441 European Journal of Haematology http://hdl.handle.net/20.500.13003/17434 31804029 L2004285464 2-s2.0-85079714883 https://hdl.handle.net/20.500.12105/23047 513964200001 Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%-40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot identify a very high-risk (HR) subset. The MD Anderson Cancer Center reported a score in the prerituximab era exclusively considering tumor-related variables: Tumor Score (TS). We aim to validate TS in the rituximab era and to analyze its current potential role. Methods From GELTAMO DLBCL registry, we selected those patients homogeneously treated with R-CHOP (n = 1327). Results: Five-years PFS and OS were 62% and 74%. All variables retained an independent prognostic role in the revised TS (R-TS), identifying four different risk groups, with 5-years PFS of 86%, 71%, 50%, and very HR (28%). With a further categorization of three variables of the original TS (Ann Arbor Stage, LDH and B2M), we generated a new index that allowed an improvement in HR assessment. Conclusions: (a) All variables of the original TS retain an independent prognostic role, and R-TS remains predictive in the rituximab era; (b) R-TS and additional categorization of LDH, B2M, and AA stage (enhanced TS) increased the ability to identify HR subsets. eng Diffuse large B-cell lymphoma International prognostic index Prognosis Score Tumor score Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era research article